Pre-Launch Planning for Pharma: Timeline and Milestones

A pharmaceutical brand launch is one of the most complex commercial undertakings in any industry. The average cost to bring a new drug to market exceeds $2.6 billion, and the commercial launch window is unforgiving. Brands that fail to build momentum in their first six months rarely recover. Yet many launch teams underestimate the sheer volume of pre-launch work required across clinical, regulatory, market access, commercial, and digital functions.

This article lays out a structured pre-launch planning timeline spanning 24 months before launch through the final 6-month countdown. Whether you are launching a first-in-class oncology biologic or a differentiated primary care therapy, the milestones below provide a framework that can be adapted to your therapeutic area, competitive landscape, and organizational structure.

The 24-Month Pre-Launch Framework

Successful pharma launches do not begin at FDA approval. They begin 18 to 24 months before the expected launch date, with a series of strategic, operational, and analytical milestones that build the commercial infrastructure needed to compete on day one. The framework below divides pre-launch into four phases, each with distinct deliverables and cross-functional dependencies.

Phase 1: Foundation (L-24 to L-18)

KOL Identification and Mapping

The foundation of any successful launch is a deep understanding of the key opinion leaders who will shape the treatment landscape. At L-24, the medical affairs team should begin systematic KOL identification using a multi-dimensional scoring approach that goes beyond publication counts.

An effective KOL mapping exercise evaluates physicians across five dimensions: clinical expertise (publications, trial involvement), conference influence (session chairs, plenary speakers), digital presence (social media engagement, webinar participation), prescription influence (total Rx volume and peer referral patterns), and network centrality (connections to other high-prescribing physicians). Each dimension is scored on a 1-5 scale, and physicians are tiered into Tier 1 (national), Tier 2 (regional), and Tier 3 (local) designations.

Most launch teams identify 50-80 Tier 1 KOLs, 200-400 Tier 2 regional leaders, and 1,000+ Tier 3 local influencers. The medical science liaison (MSL) team should begin engagement with Tier 1 KOLs by L-20, focusing on disease state education and clinical data discussion rather than product promotion.

Market Research and Competitive Intelligence

Quantitative market research should begin at L-24 with a combination of HCP attitude surveys, patient journey mapping, and claims data analysis. The goal is to understand the current treatment algorithm, identify switching barriers, map the competitive pipeline, and quantify the addressable patient population.

Key research deliverables in this phase include: total addressable market (TAM) sizing, unmet need quantification by segment, current treatment share distribution, HCP willingness to switch, patient funnel analysis, and payor landscape mapping. Budget allocation for market research typically ranges from $500K to $2M depending on therapeutic area complexity.

Phase 2: Build (L-18 to L-12)

Brand Identity and Positioning

Brand positioning development should begin at L-18 with the creative agency of record. This involves crafting the brand's unique value proposition, developing the visual identity system, and creating the core message platform that will be adapted across all channels. Positioning work should be tested with HCP focus groups and refined through at least two rounds of quantitative message testing.

By L-14, the brand team should have finalized the core positioning statement, brand name (if not already established), tagline, and visual identity guidelines. These assets form the foundation for all downstream content development.

MLR Process Setup

The Medical-Legal-Regulatory (MLR) review process is often a major bottleneck for launch readiness. Establishing an efficient MLR workflow at L-18 prevents the content crunch that derails many launches in the final months. This includes setting up the Veeva Vault PromoMats instance, establishing reviewer roles and approval workflows, creating submission templates, and defining review SLAs for each content type.

Launch teams should target the following MLR cycle time benchmarks: promotional emails (5-7 business days), digital banners (5-7 days), print leave-behinds (7-10 days), speaker slide decks (10-14 days), and website content (10-14 days). Building a modular content library where pre-approved content components can be assembled without full MLR review can reduce cycle times by 40-60%.

Digital Platform Architecture

The digital infrastructure for a modern pharma launch requires planning 12-18 months before go-live. This includes the HCP-facing product website, approved email platform integration with Veeva CRM, eSampling portal, digital engagement tracking, and analytics infrastructure.

Critical digital platform decisions include: content management system selection (Veeva Vault vs. headless CMS), HCP authentication approach, personalization engine integration, analytics and tag management implementation, and compliance with regional data privacy regulations (HIPAA, GDPR where applicable). The digital team should have the HCP website in staging by L-12 and ready for MLR review by L-10.

Phase 3: Activate (L-12 to L-6)

Field Force Planning and Hiring

Field force sizing and hiring is one of the highest-stakes pre-launch decisions. Too few reps and the brand cannot generate sufficient HCP awareness and trial. Too many reps and the cost per call balloons, dragging down launch ROI. The optimal approach combines target HCP counts, desired call frequency, geography-based travel time modeling, and competitive rep density analysis.

The hiring timeline should follow this sequence: territory design completed by L-12, headcount approved by L-11, recruitment begins at L-10, all hires completed by L-7, and training concludes by L-5. Training should cover clinical data, competitive positioning, objection handling, approved messaging, CRM usage, and compliance protocols.

Payer Strategy and Market Access

Market access planning begins at L-12 with payer landscape analysis, health economics and outcomes research (HEOR) dossier preparation, and initial outreach to key commercial payers and pharmacy benefit managers. The goal is to secure favorable formulary positioning by launch day, or at minimum to have a clear access roadmap for the first six months post-launch.

Key deliverables include the AMCP Format dossier, budget impact models, comparative effectiveness analyses, and patient access program design (copay cards, patient assistance programs). Brands with complex access strategies (step therapy, prior authorization) should plan for dedicated hub services and field reimbursement specialist support from day one.

Analytics Infrastructure

A modern pharma launch requires robust analytics infrastructure to track performance across all channels from day one. This means having data integrations, dashboards, and reporting workflows built and tested before launch. The analytics team should deliver: a unified HCP-level data layer integrating CRM, Rx, digital, and claims data; a launch metrics dashboard with daily/weekly/monthly reporting cadences; an attribution model framework (even if initial model is simple); and alert systems for tracking anomalies in prescribing patterns.

Brands that invest in analytics infrastructure before launch consistently outperform those that build reporting capabilities reactively. Data from IQVIA shows that brands with pre-built analytics dashboards achieve 15-20% faster market share growth in the first year compared to those without.

Phase 4: Launch Countdown (L-6 to L-0)

Pre-Launch Awareness and KOL Briefings

The final six months focus on activating everything built in the prior phases. Medical affairs should conduct KOL advisory boards, scientific exchange briefings, and congress presentations (data permitting) to build clinical awareness. Commercial teams should execute pre-launch awareness campaigns targeting high-priority HCPs through digital channels, approved email, and MSL engagement.

Key activities in this phase include: Tier 1 KOL pre-launch briefings (L-6 to L-4), advisory board meetings to refine messaging and gather feedback (L-5 to L-3), congress exhibit and symposium planning for first post-launch congress (L-4), speaker program recruitment and training (L-3 to L-1), and pre-launch digital awareness campaigns (L-2 to L-0).

Field Force Deployment

By L-2, the field force should be fully deployed and calling on target HCPs with disease state education materials. On launch day, reps transition immediately to branded messaging with the approved label. The first 30 days of field activity are critical: brands that achieve 80%+ call plan completion in month one see significantly stronger prescription uptake in months two through six.

Launch Readiness Checklist

Common Pre-Launch Pitfalls

After studying dozens of pharma launches, several recurring pitfalls emerge that teams can avoid with proper planning:

• Delayed MLR submissions: Content development often starts too late, creating a bottleneck in the final three months when everything needs approval simultaneously. Begin content development at L-14 and submit on a rolling basis.
• Underinvesting in digital infrastructure: Teams that allocate less than 15% of their launch budget to digital channels consistently underperform on HCP awareness metrics. Digital should be a core pillar, not an afterthought.
• Field force sizing based on historical norms: Many teams size their field force based on what the organization has done for previous launches rather than what the data suggests. Use a calculator-driven approach incorporating target counts, call frequency, and geography.
• Neglecting analytics until post-launch: Teams that build dashboards and data integrations after launch lose the critical first 90 days of performance tracking. Analytics infrastructure should be ready by L-3 at the latest.
• Insufficient KOL engagement depth: Briefing KOLs once is not enough. The most successful launch teams engage Tier 1 KOLs 4-6 times during pre-launch through a mix of advisory boards, clinical discussions, and scientific exchange.

Budget Allocation Benchmarks

Pre-launch investment varies significantly by therapeutic area and competitive intensity, but the following benchmarks provide a reference framework:

The pre-launch phase is where launch success is ultimately determined. Brands that invest early in KOL relationships, field force readiness, and digital infrastructure create a compounding advantage that accelerates post-launch adoption. The teams that scramble in the final three months are the ones that underperform in the first year. Start early, plan thoroughly, and execute with discipline.